已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

医学 肝硬化 疾病 脂肪肝 内科学 肝病 胃肠病学
作者
Fasiha Kanwal,Jennifer R. Kramer,Liang Li,Yu‐Xiao Yang,Yumei Cao,Xian Yu,Ronald Samuel,Basim Ali,Roxanne Desiderio,George T. Cholankeril,Mandeep Singh Bajaj,Hashem B. El‐Serag,Steven M. Asch
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:184 (11): 1314-1314 被引量:157
标识
DOI:10.1001/jamainternmed.2024.4661
摘要

Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing cause of cirrhosis. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in improving liver inflammation in patients with MASLD. Objective: To determine whether use of GLP-1 RAs is associated with lower risk of developing cirrhosis and its complications, including decompensation and hepatocellular cancer (HCC), among patients with MASLD. Design, Setting, and Participants: This retrospective cohort study with an active comparator, new-user design used data from the national Veterans Health Administration Corporate Data Warehouse and Central Cancer Registry. Patients with MASLD and diabetes who were seen at 130 Veterans Health Administration hospitals and associated ambulatory clinics and who initiated either a GLP-1 RA or dipeptidyl peptidase 4 inhibitor (DPP-4i) between January 1, 2006, and June 30, 2022, were included. Patients were followed up from baseline until one of the study outcomes or the end of the study period (December 31, 2022), whichever came first. Exposures: Each GLP-1 RA new user was propensity score matched in 1:1 ratio to a patient who initiated a DPP-4i during the same month. Separate analyses were conducted among patients without and with cirrhosis at baseline. Main Outcomes and Measures: For patients without cirrhosis, the primary outcome was progression to cirrhosis defined by validated diagnoses codes or a noninvasive marker of liver fibrosis, and secondary outcomes were cirrhosis complications defined both as a composite and individual complications, including decompensation, HCC, or liver transplant, and all-cause mortality. For patients with cirrhosis, the primary outcome was a composite outcome of cirrhosis complications, and secondary outcomes were decompensation, HCC, and all-cause mortality. Results: Of 16 058 patients who initiated GLP-1 RAs, 14 606 did not have cirrhosis (mean [SD] age, 60.56 [10.31] years; 13 015 [89.1%] male), and 1452 had cirrhosis (mean [SD] age, 66.99 [7.09] years; 1360 [93.7%] male) at baseline. These patients were matched to an equal number of patients who initiated a DPP-4i. In patients without cirrhosis, GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of cirrhosis (9.98 vs 11.10 events per 1000 person-years; hazard ratio [HR], 0.86; 95% CI, 0.75-0.98). Similar results were seen for the secondary outcomes. GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of the composite outcome of cirrhosis complications (1.89 vs 2.55 events per 1000 person-years; HR, 0.78; 95% CI, 0.59-1.04) and mortality (21.77 vs 24.43 events per 1000 person-years; HR, 0.89; 95% CI, 0.81-0.98). There were no associations between GLP-1 RA use and outcomes in patients with cirrhosis. Conclusions and Relevance: In this cohort study, GLP-1 RA use was associated with a lower risk of progression to cirrhosis and mortality among patients with MASLD and diabetes. The protective association was not seen in patients with existing cirrhosis, underscoring the importance of treatment earlier in the disease course.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
唐唐发布了新的文献求助10
刚刚
1秒前
1秒前
2秒前
八云紫完成签到,获得积分10
3秒前
3秒前
科研通AI6.4的应助被廖小明采纳,获得10
5秒前
chenlong完成签到 ,获得积分10
6秒前
ophir发布了新的文献求助10
7秒前
我是老大的应助被活泼的鼠标采纳,获得10
7秒前
思源的应助被Zxy采纳,获得10
7秒前
可爱的函函的应助被FF采纳,获得10
8秒前
8秒前
小人物的坚持完成签到 ,获得积分0
9秒前
自信萃完成签到 ,获得积分10
9秒前
10秒前
Cakoibao的应助被哈哈哈采纳,获得10
13秒前
13秒前
任明艳完成签到 ,获得积分10
14秒前
14秒前
15秒前
15秒前
15秒前
wanci的应助被我看看怎么个事采纳,获得10
15秒前
Crssss的应助被我看看怎么个事采纳,获得10
15秒前
15秒前
15秒前
Crssss的应助被我看看怎么个事采纳,获得10
15秒前
alex的应助被我看看怎么个事采纳,获得10
15秒前
alex的应助被我看看怎么个事采纳,获得10
15秒前
16秒前
16秒前
xu发布了新的文献求助10
16秒前
Muller完成签到,获得积分10
17秒前
司新颖发布了新的文献求助30
20秒前
SciGPT的应助被忧郁自行车采纳,获得30
22秒前
布洛芬发布了新的文献求助10
22秒前
22秒前
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184723
求助须知:如何正确求助?哪些是违规求助? 9573702
关于积分的说明 21832740
捐赠科研通 7782090
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481054